These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25577039)

  • 1. Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.
    Henderson JA; Bilimoria D; Bubenik M; Cadilhac C; Cottrell KM; Denis F; Dietrich E; Ewing N; Falardeau G; Giroux S; L'Heureux L; Liu B; Mani N; Morris M; Nicolas O; Pereira OZ; Poisson C; Reddy TJ; Selliah S; Shawgo RS; Vaillancourt L; Wang J; Xu J; Chauret N; Berlioz-Seux F; Chan LC; Das SK; Grillot AL; Bennani YL; Maxwell JP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):948-51. PubMed ID: 25577039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
    Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.
    Ramdas V; Talwar R; Banerjee M; Joshi AA; Das AK; Walke DS; Borhade P; Dhayagude U; Loriya R; Gote G; Bommakanti A; Sivaram A; Agarwal G; Goswami A; Nigade P; Mehta M; Patil V; Modi D; Kumar H; Mallurwar S; Dash A; Modi F; Kuldharan S; Srivastava P; Singh M; Narasimham L; Gundu J; Sharma S; Kamboj RK; Palle VP
    J Med Chem; 2019 Dec; 62(23):10563-10582. PubMed ID: 31710479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Coburn CA; Nair AG; Wong M; Rosenblum SB; Zhou G; Dwyer MP; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Kim SH; Zeng Q; Selyutin O; Chen L; Masse F; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Lin M; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3414-20. PubMed ID: 27394665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gottwein JM; Pham LV; Mikkelsen LS; Ghanem L; Ramirez S; Scheel TKH; Carlsen THR; Bukh J
    Gastroenterology; 2018 Apr; 154(5):1435-1448. PubMed ID: 29274866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
    Amblard F; Zhang H; Zhou L; Shi J; Bobeck DR; Nettles JH; Chavre S; McBrayer TR; Tharnish P; Whitaker T; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2031-4. PubMed ID: 23466233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of fluorobenzimidazole HCV NS5A inhibitors.
    Randolph JT; Flentge CA; Donner P; Rockway TW; Patel SV; Nelson L; Hutchinson DK; Mondal R; Mistry N; Reisch T; Dekhtyar T; Krishnan P; Pilot-Matias T; Stolarik DF; Beno DWA; Wagner R; Maring C; Kati WM
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5462-5467. PubMed ID: 27780635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.
    Lim PJ; Gallay PA
    Curr Opin Virol; 2014 Oct; 8():30-7. PubMed ID: 24879295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.
    Belema M; Meanwell NA
    J Med Chem; 2014 Jun; 57(12):5057-71. PubMed ID: 24749835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.
    Boucle S; Tao S; Amblard F; Stanton RA; Nettles JH; Li C; McBrayer TR; Whitaker T; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3711-5. PubMed ID: 26099532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus NS5A inhibitors and drug resistance mutations.
    Nakamoto S; Kanda T; Wu S; Shirasawa H; Yokosuka O
    World J Gastroenterol; 2014 Mar; 20(11):2902-12. PubMed ID: 24659881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent macrocyclic HCV NS5A inhibitors.
    Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Insight into the Chemical Space and ADME Features of Small Molecule NS5A Inhibitors.
    Ivanenkov YA; Veselov MS; Shakhbazyan AG; Aladinskiy VA; Aladinskaya AV; Yartseva SM; Majouga AG; Vantskul AS; Leonov SV; Ivachtchenko AV; Koteliansky VE
    Curr Top Med Chem; 2016; 16(12):1372-82. PubMed ID: 26585933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.